Home >
Medicine Info >
Jalra-M 50 mg/850 mg Tablet
Loading interface...

Jalra-M 50 mg/850 mg Tablet

Manufactured byUSV LTD
ContainsMetformin (850 mg) + Vildagliptin (50 mg)
Description
Jalra-M 50 mg/850 mg Tablet is a combination medicine that consists of Metformin and Vildagliptin. It is used in the management of Type 2 diabetes in adults. It works by increasing insulin release and improving your body's response to insulin. It also decreases glucose production, thereby further lowering your blood sugar levels. Jalra-M 50 mg/850 mg Tablet has some side effects include headache, dizziness, nausea/vomiting, diarrhoea, etc. Consult your doctor if these symptoms stay for a long time or if they become severe. It lowers blood sugar levels and this may make you feel hungry, irritable, confused, anxious, or shaky. It is always recommended to eat or drink a fast-acting source of sugar (fruit juice, candy, raisins, etc.) to quickly treat these symptoms. Jalra-M 50 mg/850 mg Tablet should be taken as advised by your doctor. Take it at the same time every day to maintain a constant level of this medicine in your body. Do not skip a dose or discontinue the treatment as it may cause an increase in your blood sugar levels. It is advised to follow proper exercise and diet along with this medicine to get better results. Jalra-M 50 mg/850 mg Tablet is not recommended if you are allergic to it. Jalra-M 50 mg/850 mg Tablet may interact with other medicines, so inform your doctor if you are taking any medicines and/or supplements. Inform your doctor if you have kidney or liver problems before taking this medicine. This medicine is not recommended for children below 18 years of age. Consult your doctor if you are pregnant, planning a pregnancy or are breastfeeding.
QUICK LINKS:
Side effectsConcernsUsageRelated products

Side effects

Major & minor side effects for Jalra-M 50 mg/850 mg Tablet

  • Headache
  • Dizziness
  • Weakness or sleepiness
  • Loss of appetite
  • Sore throat
  • Change in taste
  • Swelling of face, lips, eyelids, tongue, hands and feet
  • Nausea and vomiting
  • Diarrhoea
  • Abdominal pain
  • Lactic acidosis
  • Chest discomfort
  • Low blood sugar levels
  • Belching and heartburn
  • Swollen joints

Uses of Jalra-M 50 mg/850 mg Tablet

What is it prescribed for?

  • Type II Diabetes
Read More
Concerns

Commonly asked questions

  • How long does it take for this medicine to take effect?
    The effects of Jalra-M 50 mg/850 mg Tablet can be observed within 1-3 hours after taking it.
  • How long do the effects of this medicine last?
    The amount of time for which Jalra-M 50 mg/850 mg Tablet remains active in your body is not known.
  • Is it safe to consume alcohol while taking this medicine?
    Consumption of alcohol is not recommended during treatment with Jalra-M 50 mg/850 mg Tablet as it may increase the risk of lactic acidosis (increased blood lactic acid levels). It may also decrease the effectiveness of this medicine in controlling blood sugar levels.
  • Is this a habit forming medicine?
    No habit forming tendency has been reported with Jalra-M 50 mg/850 mg Tablet.
  • Can this medicine be taken during pregnancy?
    Jalra-M 50 mg/850 mg Tablet is not recommended to be used in pregnancy due to the lack of insufficient information regarding its safety and efficacy. Consult your doctor if you are pregnant or planning a pregnancy before using this medicine.
  • Can this medicine be taken while breast-feeding?
    Jalra-M 50 mg/850 mg Tablet may passes into breastmilk. This medicine is not recommended while breastfeeding due to the increased risk of low blood sugar levels in your baby. Consult your doctor if you are breastfeeding before using this medicine.

Allergy

Avoid taking Jalra-M 50 mg/850 mg Tablet if you are allergic to it. However, seek immediate medical attention if you notice any symptoms such as skin rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, breathing difficulty, etc.

Type I Diabetes

Type 1 diabetes, also known as insulin-dependent diabetes, is a chronic condition in which the pancreas produces little or no insulin. Symptoms include increased thirst, frequent urination, hunger, fatigue, and blurred vision. Jalra-M 50 mg/850 mg Tablet is not recommended if you have type 1 diabetes.

Diabetic ketoacidosis

Jalra-M 50 mg/850 mg Tablet is not recommended for use if you have a known history of diabetic ketoacidosis due to the increased risk of worsening your condition.

Severe liver disease

Jalra-M 50 mg/850 mg Tablet is not recommended if you have severe liver conditions due to an increased risk of liver damage.

Severe kidney diseases

Jalra-M 50 mg/850 mg Tablet is not recommended if you have severe kidney conditions as this medicine eliminates through the kidneys, impaired kidney function may lead to its accumulation and causes severe side effects.

Metabolic acidosis

Metabolic acidosis is characterized by high levels of acids in your blood. The symptoms include thirst, frequent urination, vomiting, abdominal pain, weakness, muscle cramps, etc. Jalra-M 50 mg/850 mg Tablet is not recommended if you have metabolic acidosis as this medicine may worsen your condition.
Warnings for special population

Pregnancy

Jalra-M 50 mg/850 mg Tablet is not recommended to be used in pregnancy due to the lack of insufficient information regarding its safety and efficacy. Consult your doctor if you are pregnant or planning a pregnancy before using this medicine.

Breast-feeding

Jalra-M 50 mg/850 mg Tablet may passes into breastmilk. This medicine is not recommended while breastfeeding due to the increased risk of low blood sugar levels in your baby. Consult your doctor if you are breastfeeding before using this medicine.
General warnings

Liver disease

Jalra-M 50 mg/850 mg Tablet may increase the risk of liver damage. If you have liver problems, your doctor may suggest tests to monitor your liver functions while on treatment with this medicine.

Skin disorders

Jalra-M 50 mg/850 mg Tablet may increase the risk of skin lesions. Unusual symptoms like blistering or ulceration (open sores) should be reported to your doctor immediately.

Arthralgia

Jalra-M 50 mg/850 mg Tablet should be used with caution if you have a history of arthralgia (a condition of physical discomfort at your joints) as it may worsen your condition. Your doctor may adjust the dose of this medicine or may suggest a suitable alternative based on your condition.

Use in children

Jalra-M 50 mg/850 mg Tablet is not recommended for use in children below 18 years of age due to a lack of safety and efficacy data.

Kidney diseases

Jalra-M 50 mg/850 mg Tablet should be used with caution if you have kidney problems as it may increase the risk of lactic acidosis (high levels of lactic acid in the blood). Your doctor may adjust the dose of this medicine or may suggest a suitable alternative based on your condition.

Driving or operating machines

Jalra-M 50 mg/850 mg Tablet may cause low blood sugar levels and dizziness which may affect your mental alertness. Avoid driving vehicles or operating machines if you experience these symptoms after taking this medicine.

Diarrhoea

Jalra-M 50 mg/850 mg Tablet may cause diarrhoea when the treatment is started. In most cases, diarrhoea subsides by itself. Contact your doctor if the problem persists for longer durations.

Lactic acidosis

Jalra-M 50 mg/850 mg Tablet may cause lactic acidosis. This risk is especially higher if you have a history of heart diseases, kidney diseases, etc. Report any unusual symptoms to the doctor immediately. Your doctor may suggest a suitable alternative based on your clinical condition.

Surgery

Jalra-M 50 mg/850 mg Tablet is not recommended to be used during surgery due to the increased risk of high levels of lactic acid in the blood which can affect the result of the surgery. If you are taking this medicine, inform your doctor before undergoing any surgery. Your doctor may suggest discontinuing the treatment before surgery.

Missed Dose

Do not skip a dose of Jalra-M 50 mg/850 mg Tablet. If you forget to take a dose of this medicine, take it as soon as you remember. If it is time for your next dose, skip the missed one. Do not double the dose to compensate for the missed one.

Overdose

Never take more than the prescribed dose. Seek emergency medical help if you suspect that you might have taken an overdose of Jalra-M 50 mg/850 mg Tablet.
All drugs interact differently for person to person. You should check all the possible interactions with your doctor before starting any medicine.
Interaction with Alcohol

Description

N/A

Instructions

Consumption of alcohol is not recommended during treatment with Jalra-M 50 mg/850 mg Tablet as it may increase the risk of lactic acidosis (increased blood lactic acid levels). It may also decrease the effectiveness of this medicine in controlling blood sugar levels.
Interaction with Medicine

Clozapine

Estradiol

Gatifloxacin

Corticosteroids

Iodinated Contrast Media

Dexamethasone

Acetazolamide

ACE inhibitors

Cimetidine

Disease interactions

Pancreatitis

Pancreatitis is the swelling of the pancreas. Jalra-M 50 mg/850 mg Tablet may increase the risk of pancreatitis. It should be used with caution if you have pre-existing pancreatitis. Your doctor may adjust the dose f this medicine or may suggest an alternative medicine based on your condition.

Cardiac failure

Cardiac failure occurs when your heart muscle does not pump blood as well as it should. Jalra-M 50 mg/850 mg Tablet should be used with caution if you have a history of this condition. Your doctor may adjust the dose f this medicine or may suggest an alternative medicine based on your condition. Your doctor may suggest tests to monitor your heart function as needed while on treatment with this medicine.

Vitamin B12 deficiency

Jalra-M 50 mg/850 mg Tablet should be used with caution if you have vitamin B12 deficiency. This medicine interferes with the absorption of Vitamin B12 in your body. Inform your doctor if you are taking vitamin B12 supplements before taking this medicine.
Food interactions
Information not available.
Lab interactions
Information not available.
This is not an exhaustive list of possible drug interactions. You should consult your doctor about all the possible interactions of the drugs you’re taking.
Take Jalra-M 50 mg/850 mg Tablet with food or as prescribed by your doctor. Avoid taking more than the prescribed dose as it may increase the risk of side effects. Do not stop taking Jalra-M 50 mg/850 mg Tablet without consulting your doctor. Your doctor may monitor your blood sugar levels to check that your diabetes is under control. Maintain a proper diet and do regular exercise to get maximum benefits of the treatment.
Miscelleneous

To be taken with food

To be taken as instructed by doctor

May cause sleepiness

How it works
Jalra-M 50 mg/850 mg Tablet is a combination of Metformin and Vildagliptin. Metformin works by improving your body’s response to insulin and decreasing glucose (sugar) production in the liver. This helps in lowering the increased blood sugar levels. Vildagliptin works by promoting insulin release from the pancreas and also increasing the activity of the hormone (Glucagon) which helps to control blood sugar levels.
Legal Status

Approved

Unknown

Unknown

Approved

Classification

Category

Antidiabetic combinations, Oral Biguanides, Dipeptidyl peptidase 4 inhibitors

Schedule

Schedule H

Medicines.org.uk. 2021. Eucreas 50 mg/1000 mg film-coated tablets - Summary of Product Characteristics (SmPC) - (emc). [online] Available at: < [Accessed 25 August 2021].

https://www.medicines.org.uk/emc/product/11521/smpc>

Guildlink.com.au. 2021. [online] Available at: < [Accessed 15 September 2021].

http://www.guildlink.com.au/gc/ws/nv/pi.cfm?product=nvpgamor10216>

Dailymed.nlm.nih.gov. 2021. DailyMed - Metformin HCL tablet. [online] Available at: < [Accessed 7 July 2021].

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d98aea3-35ba-447a-b88f-a5a20b612b2f>

Medicines.org.uk. 2021. Galvus 50 mg Tablets - Summary of Product Characteristics (SmPC) - (emc). [online] Available at: < [Accessed 7 July 2021].

https://www.medicines.org.uk/emc/medicine/20734>

Medicines.org.uk. 2021. [online] Available at: < [Accessed 25 August 2021].

https://www.medicines.org.uk/emc/files/pil.594.pdf>

Ema.europa.eu. 2021. [online] Available at: < [Accessed 15 September 2021].

https://www.ema.europa.eu/en/documents/product-information/eucreas-epar-product-information_en.pdf>
Loading related questions...
Something doesn’t feel right?
Report an error

Information on this page was last updated on 21 Sep 2021

Disclaimer

We’ve made all possible efforts to ensure that the information provided here is accurate, up-to-date and complete, however, it should not be treated as a substitute for professional medical advice, diagnosis or treatment. Practo only provides reference source for common information on medicines and does not guarantee its accuracy or exhaustiveness. The absence of a warning for any drug or combination thereof, should not be assumed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Practo does not assume any responsibility for any aspect of healthcare administered with the aid of information provided above. If you have any doubts about your medication then we strongly recommend that you consult with your doctor, nurse or healthcare provider. See detailed T&C here.